Member Info for CHELSEA7

Morning, a very good post. You are seeing this from a different level, one which i agree on, lets see what the day brings.

I enjoyed reading back on a few posts the last couple of weeks, and would ask you to back up the many you have made that i fail to see any logic in. For that very reason i am loathed to continue to knock the points you have raised, and would ask you to clearly state the logic you hold, in ine particular area perhaps that being we would benefit at this stage from a mass dilution, raising not enough funds to enter into trials to hit inflection points a s you see we will to enjoy the benefits you state in anyears or two time.

We have no idea as to what is being negotiated now in that respect, just seems odd we can ignore that and presume nothing will be the outcome and emergency measures must be taken down now. How can such mass dilution raise the funds we need to be able to prove up more data? Lokkining forward to your reply which has caused a lot of disbelief.

Fell asleep Friday about 5.00, just woken up after midninght today, and i much prefer reading back in sequence over a 100 posts then just the odd few/

Great posts by Ray, Crumbs and WILD, Chester too, all reinstate the possibilities here, and are at odds with Knowlesi claims that all is very unwell and 1p will be seen before we reap the rewards in 2020 or has it changed now to 2021?

I wasn"t aware dracula that you had a good holding here, and semantics apart wish you good luck as i do with eberyone on it. I thik Wild called it very right when saying the best stragedy was to buy the day before big news, just shows how difficult it is to call right, but the sheer scope for such news is immense and carries into many platforms.

My own position is very clear, an average sub 15p, but looking forward to the months/weeks ahead, we have seen some remarkarkable rises on AIM and just hope this is another waiting to happen. We still have Knowlesi talking everything down, whilst seeking his entry at 1p, but he ensures us we can be so off track an d still suceed in 2020/2021/ O course we could raise millions more shares at 1/2p a share, that would really help wouldn"t it.!! It at least ensures financial suicide but he knows best.

Very clear to see who is well researched here, happy to read their posts and views, and we all want the same thing, to see SCIB 1/2 and Moditope proven to be a better standard of care that that currently available. The glycan TCR package too will hopefully go some way to funding it and i am very confident in our new hirers, lets get behing Scancell, delivering is in the interests of all, and the tens of thousands of patients lives we could save and extend, that is my interest here. GL All, and very good luck, and well researched guys.

Scancell extends Moditope collaboration with Karolinska Institute

Â

Broadens cancer immunotherapy development potential for Moditope platform

Â

Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that it has extended its strategic research collaboration with the Rheumatology Unit at the Karolinska Institute Sweden. The expanded agreement will explore the potential of the Moditope® platform to develop multiple immunotherapeutic agents for a range of different cancers.

Â

Scancell's Moditope® platform technology uses citrullinated tumour-associated peptide epitopes to stimulate the production of killer CD4+ T cells.  The activated T cells seek out and kill tumour cells that would otherwise be hidden from the immune system.  Scientists at the Rheumatology Unit at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, previously uncovered an essential role for citrullinated proteins in the pathogenesis of the autoimmune disease rheumatoid arthritis.

Â

This collaboration builds on the previous agreement, announced on 11 March 2016, which allowed the parties to explore how immunity to citrullinated proteins is involved in the control of tumour growth for the development of cancer vaccines.  Broadening this agreement will allow further investigation into the potential of Moditope® for any cancer immunotherapy, including, T-Cell Receptor based therapeutics.

Â

Professor Lindy Durrant, Chief Scientific Officer of Scancell, commented:

Â

"We are pleased to have broadened our research collaboration with Professor Klareskog, Professor Malmström and their colleagues at the Karolinska Institute. Our research has shown that citrullinated proteins are involved in the control of tumour growth and we believe that this expanded collaboration will help us to   develop Moditope®, not only for use in cancer vaccines, but also as part of other cancer immunotherapy approaches."

Â

Professor Lars Klareskog, MD, PhD, at Karolinska Institutet, added:

Â

"The collaboration with Scancell will allow us to investigate the relationships between autoimmunity and cancer and the therapeutic opportunities that may be uncovered from such studies."

Â

As RG would say.............""another brick in the wall""!!! Lining up aren"t they? ATB

Morning chester, that RNS.............................

Scancell to collaborate with BioNTech
Tue, 9th Jan 2018 07:00
RNS Number : 1654B
Scancell Holdings Plc
09 January 2018
Â
09 January 2018

Â

Scancell Holdings Plc

("Scancell" or the "Company")

Â

Scancell to collaborate with BioNTech to investigate T cell receptor based therapeutics for the treatment of cancer

Â

Agreement expands potential therapeutic utility of Moditope® to adoptive T cell therapy

Â

Scancell Holdings plc, ('Scancell' or the 'Company') the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has entered into a research collaboration with BioNTech for the potential development of innovative, T cell receptor based therapeutics for the treatment of cancer. This research collaboration combines Scancell's Moditope® immunotherapy platform and BioNTech's platform technology for high-throughput cloning and characterisation of naturally selected T cell receptors.

Â

Moditope® represents a completely new class of potent and selective immunotherapy agents which could have a profound effect on the way that cancer immunotherapies are developed. It acts by stimulating the production of CD4+ T cells using citrullinated tumour-associated peptide epitopes which overcome self-tolerance and destroy tumour cells. The technology overcomes the immune suppression induced by tumours themselves without the need for checkpoint blockade inhibitors, thereby allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system.

Â

Under the terms of the agreement, Scancell and BioNTech will enter into an initial research collaboration to discover and characterise T cell receptors specific for citrullinated epitopes from vimentin and enolase. These epitopes form the basis of Scancell's first Moditope® development candidate, Modi-1. Upon completion of these studies, BioNTech will have the exclusive option to enter into a licence agreement for the development of cell receptor based therapeutics that are specific to Modi-1 epitopes.

Â

Prof Lindy Durrant, Chief Scientific Officer of Scancell, commented: "We are delighted to be working with BioNTech, one of Europe's new immuno-oncology power-houses, to investigate the development of targeted immunotherapies for the treatment of cancer. Pre-clinical data from our Moditope® platform has shown unprecedented anti-tumour effects can be delivered without the need for checkpoint inhibition. We believe that this, combined with BioNTech's engineered T cells specific to Moditope® epitopes, could have great potential as a novel immunotherapy."

Â

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)

Doubt very much they would have put a timeline on it, but re read this agreememnt with Karolinska.................

From March 27th, always worth a read........................

Trinity Delta
?

@trinity_delta
Follow Follow @trinity_delta
More
Our Company Pages tab is the portal to company-specific info on our current research coverage: https://www.trinitydelta.org/company-pages/

@BGenBio @BONESUPPORT_AB @e_Therapeutics @HChiMed @KindConsumer @MaxCyte_info @MereoBioPharma @NexstimOyj @scancellpharma @Tissue_Regenix

Just wanted to welcome yellow green to the BB, and Ray Pointer for some excellent posts. The disconnect between the SP and the companies advancement, let alone the IP is truly staggering. Harsh isn"t it, that opening the door to so many new treatments has not revalued us at all, but i think we all know what will, and the disconnect that exists now could be far away when that news hits. I think we have plenty more to hear from Sweden who adorned LD with that award. Our collaboration with Karolinska has been extended for a second termla very inportant role in their further development, looking forward to hearing much more.

Morning All, smily faces, another week has gone.

No not as much as i would like too, and hoping others can bring more clarity to what effects Scancell in relevance,

Managed to wake for the RNSs every day, and straight back to sleep shortly after, i found chesters post warming and welcome. So achieving what i set out to catch up on sleep, and priotirise was important to me, very grateful to do that toNot much has really changed, volume is low and when we get a 100k buy, two 50k sells at 5.50 appear to negate them

still realistic as to the hopes we have, in our pipeline, i thing chester has hilighted that only too well.

Keep the faith, it is frustrating, hoping with you every day. ATB

Evening Guys, Ovarien Cancer........................

https://www.cancertherapyadvisor.com/home/news/conference-coverage/society-of-gynecologic-oncology-sgo/sgo-2019/dendritic-cell-vaccine-ovarian-cancer-induce-anti/?utm_source=newsletter&utm_medium=email&utm_campaign=cta-update-20190328&cpn=&hmSubId=mN64mG723kM1&hmEmail=jVxM0Zt7odmYiTTvEmjFPIspSuO99bAWcv7dEv1U4Vw1&NID=&dl=0&mpweb=1323-44425-5778081

Hope all well.................C7

Well a beautiful day here in London, wondered where you got to.

If you don"t mind I will pass on that and presume those bigger buys were yours.

Nothing more I would wish for than you to be right, think that goes for everyone here, but....................

Hope you enjoyed your day, TBH fed up seeing my name mentioned here, no high morals, a very simple life these days. There are a few that appreciate just logging in and getting the gist of the day, without opening 3/4 apps whilst out and TBH I enjoy sharing it. It is back to the hospital for me very soon, changed my mind about no treatment, that is what is important to me, Time to take a break from here, important decisions to make and TBVH fed up reading the carp about me. We all have limits, and events in the last couple of weeks have made me realise my limits are up, so I"ll be looking forward to the deal RNSs like everybody else. Take care

Tee hee. Have a good day

Do you have any footage of Researchers walk?

Uncanny.....................Interesting Viewpoint...............................

"".Apart from the dilution which is eveyones gripe including mine, albeit little atlternative, what you have is 4 compounds that work of which 401 is a halt to constant refinancing and dilution and 201 is a game changer!
So actually things are good and what an entry level opportunity to invest!"""

George will be happy with that!!!! Anyone know why he has chosen not to share the end Q1 news with everyone at The Investor Show??

Anyone fancy interpreting that in English, lol?

Whilst still discussing trades, who, what and how many, just wanted to repost yours of last night. An interesting post,,,,,,,,,,,,,,,,,,,,

https://www.lseg.com/areas-expertise/our-markets/turquoise/who-we-are

8.24 AND 8.29 lol.

Just seen your 6.08, such as it was last week i didn"t even call those five black trades over 2/3 minutes totalling 1.2m shares at 5.75, still significantly higher than trades in the low 5s last week. Probably were sells, but we did finish up and a couple of largish trades weren"t even delayed, except for the 500k (buy) from the 20th. So delaying buys, posting sells?

Friday was interesting for its lack of volume 121k volume of which 111k were buys despite MMs wanting shares all day up to 180k at 5.75 and didn"t get any. Yep there a few clouds remaining, as Scancell tweeted Wednesday ""another brick in the wall", lol.

You said, and i hope no more discussion on this is had,.............""".There is already enough arguing in the world lol """, well i agree and for a long time now have expressed just that, whilst that is indeed true, what i said sums up how i felt about it, and wouldn"t wish what was said on anybody else. Matter closed.

Crumbs our posts crossed at the same time, sending the same message too. i have shared quite a few conservations with CH over the last year, 2Bearing more fruit with Biontech was the original theme which hasn2t changed at all. I would be very surprised if interest was just restricted to them though. We spoke of Moditopes extraordinary potential in a range of diseases then, and see with Karolinska the potential of those uses going further too.

And as we saw last week, anything can be released at any time.

We needed some encouragement, i think last week provided some, with a lot more to come.

I felt it was a very encouraging one, despite knowing about the Moditope Patent, the glycan news wasn"t, and Lindys award was out of the blue. The recognition of so many Peers who had just one nominee to choose shows us yet again the high esteem she is held in, brings her work at Scancell to the fore, and makes me even more confident our business with the Karolinska Institute has many more legs in it than ever.

Many views have been posted as to buys and sells, the difficulty in calling them, but ultimately on Wednesday a little over 3m shares were posted up and we rose 3.68%. Whether iis are buying or selling is speculative until confirmed but considering we always knock our PI base, if it wasn"t driven by iis then an awful lot of PIs bought. I will go for the former whilst City Financial and L& G have reduced holdings, there must be upwards of 60 iis who are shareholders and could just as easily be buying especially seeing our potential and the opportunity to increase their holdings well below the Placing price. Unlikely to find out for sure as they are all outside of having to declare (so far) significant holdings.

Again if not iis we rarely see volumes like 3m in a single day, so plenty of PIs adding or new holders taking a position, and i have mentioned a few times with the benefit of speaking with a few that Scancell are being well monitored as a comeback share. I can only remember 3m traded in a day a few times, mind you the total costs of them are far less than in previous times.

We have every reason to be hopeful of a deal, with BioNTech, Karolinska and even ISA calling their interest, and according to this bb last night we don"have a matter of weeks to negotiate but at least until SEPTEMBER, depending what the BOD wish to do, Forgetting forecasters ranging from 2p-5p I just cannot see a placing taking place at that level, but with the right advisors, legal and financial and interested parties have every right to think that, however much the risk exists.

Next weeks trading will be interesting too, and we know what RNSs we want to get, any one of those could well see us back into double figures, the City Financial debacle is not our fault, just a shame we are entangled in it. From no news a few appetites have been wetted, lets hope that is maintained at worst. So too next week, looking forward too it.

Agree with that, would be good to know where those shares have gone though, although the total they are worth is no more than £1.25M. A few people have said nothing will occur with BioNTech until after the planned IPO, I disagree with that.